arth one-year price volum histori
arth high-upsid potenti discount
resum coverag inc buy rate
share price target massachusetts-bas biotechnolog
compani develop novel hemostat stop bleed sealant
control leakag traumat surgic chronic wound impetu
buy rate arth share potenti compani leverag
self-assembl peptid sap technolog platform medic barrier
key driver invest thesi includ
driver topic surgic medic barrier
util sap spontan form clear gelatin membran
sap solut spontan form clear gelatin barrier
compris nanofibr network expos ion bodili
fluid topic hemostat sealant extern wound
surgic develop intern use hook rapid
consist efficaci stop bleed less second improv
safeti profil compar current market hemostat sealant
driver satisfi unmet need across larg grow
hemostat sealant wound care market believ
versatil featur consist speed conform deep wound
biocompat clear becom competit hemostat sealant adhes
prevent barrier wound care product combin global market
product expect approach billion target
topic surgic launch project
million combin peak revenu therefor believ
platform repres appeal take-out candid larg
player medic barrier market
driver bad break dealt fda present buy opportun
discount valuat arth share reced follow decemb
announc voluntarili withdrew topic fda
submiss follow receipt question final day
review period march compani announc concern
allerg potenti believ resolv follow
propos two-month clinic studi target arth resubmit
topic receiv approv year-end
driver valuat appear attract believ market
continu overlook potenti approv follow march updat
share continu trade heavili discount valuat compar
last decemb resum coverag arth buy rate
import disclosur regul ac certif locat page report
resum coverag therapeut inc ticker arth buy rate price
target therapeut massachusetts-bas biotechnolog compani develop novel
hemostat stop bleed sealant control leakag traumat surgic chronic wound
impetu buy rate arth share potenti compani leverag self-assembl
peptid technolog platform medic barrier product
invest thesi inc arth hing four key invest driver
reason invest arth arch self-assembl peptid technolog uniqu featur
believ could translat platform medic barrier product
develop self-assembl peptid sap solut compris amino
acid long peptid spontan assembl nanofib scaffold presenc ion sinc
bodili fluid high level ion contact sap solut bodili fluid trigger assembl
nanobarri cover defect seal bleed wound sap nanobarri prevent
flow fluid contamin tissu lend potenti use varieti set includ
stop bleed control leakag organ cover wound
exhibit self-assembl peptid trigger exposur ion bodili fluid
believ gelatin membran form sever advantag current product
clear allow direct visual surgeon oper trademark crystal
clear surgeri clinician monitor heal burn chronic wound without remov
conform structur deep wound
physical-mechan mechan action see lead fast consist perform
agnost blood thinner anticoagul
made synthet l-amino acid non-immunogen carri risk infecti
transmiss swell natur resorb bodi
affect coagul platelet behavior red blood cell integr trigger inflamm
easily-manipul non-adher
page
use minimally-invas surgic procedur
formul liquid powder spray gel combin bandag spong
product
formul combin varieti drug compound includ
antibiot vasoconstrictor anesthet chemotact factor growth factor
inexpens manufactur long shelf-lif
physical-mechan mechan action provid fast consist action
sap amphiphil altern charg neutral amino acid unit long
presenc ion oppositely-charg amino acid adjac strand form ionic hydrogen bond
neutral amino acid undergo hydrophob interact spontan drive self-assembl
network nanofib process happen within second sap behav much like tini magnet
snap togeth presenc extern forc due mechan action moa
demonstr consist safeti efficaci currently-market hemostat sealant multipl
preclin anim studi especi presenc sever bleed blood thinner sourc adam
nanobiotechnol therapeut own exclus license mit
combin patent patent applic nine jurisdict cover array sap sequenc
combin applic beyond mention report highlight arch notabl
patent exhibit encourag investor review clear detail descript
physical-mechan moa variou applic sap platform could pursu
exhibit self-assembl peptid formula space-fil model bond
sourc patent
exhibit notabl patent own exclus licens
page
preclin clinic evid safeti efficaci
physical-mechan moa believ batteri preclin anim studi serv
meaning proxi perform human valid thu far one clinic
efficaci studi sinc extens evalu preclin vitro vivo studi
three vitro studi demonstr interact cell receptor kinas
enzym valid moa non-cytotox non-pyrogen
four anim studi demonstr neglig irrit non-sensit
system toxic promot normal wound heal minim inflamm
proof concept studi demonstr rapid hemostat abil bleed injuri
brain spinal cord femor arteri liver skin rat nanomedicin
collagenase-induc intracerebr hemorrhag rat nanomedicin
multipl anim studi demonstr consist abil stop bleed liver wound
presenc blood thinner
multipl anim studi demonstr superior variou popular commercially-
avail hemostat agent stop bleed follow full-thick penetr liver wound
rat well prevent gastrointestin gi adhes see exhibit
exhibit stop bleed faster competitor prevent gi adhes rat liver
success evalu two clinic studi cumul irrit evalu cie
test healthi human volunt studi evalu safeti hemostat efficaci
bleed skin wound compar water-resist dress cie test demonstr
consid irrit consist prior anim studi clinic safeti
safeti seriou one rash patient
faster time hemostasi tth control vs second
maintain second tth antiplatelet medic statist
faster control tth increas second
advers effect wound heal
believ clinic studi confirm anim data support approv extern
use topic experienc regulatori setback decemb eve
fda decis discuss detail anticip topic avail
europ extern use follow addit clinic studi evalu intern use
surgic expect run believ surgic could reach market
page
earli expect upcom intern surgic studi corrobor find anim
studi multipl tissu type
reason invest arth potenti satisfi unmet need across multipl larg
grow market hemostat sealant wound care product
approv believ could substanti market opportun hemostat sealant wound
care product medic barrier devic global market hemostat sealant expect
exceed billion global market wound care product could exceed billion
medmarket dilig report believ safeti efficaci eas
use versatil could translat meaning market share larg grow market
hemostat sealant market domin small group larg compani includ johnson
johnson jnj-nc baxter bax-nc takeda tkpyy-nc wound care market far
fragment lead hemostat/seal compani maintain posit acquisit
believ repres appeal candid sinc present opportun establish
posit market well expand larger wound care market lack domin leader
exhibit global hemostat sealant market billion
page
exhibit self-assembl nanobarri sanb satisfi drawback compet hemostat
project surgic peak annual revenu exceed million reach
estim base
peak hemostat market share project translat million peak
hemostat sale
peak european hemostat market share project translat million peak european
hemostat sale
million combin peak revenu europ gi sealant adhes
exhibit surgic market opportun hemostat
page
exhibit surgic market opportun gi sealant adhes prevent barrier
surgic gi sealant adhes prevent
within wound care market believ topic could compet favor
grow subset highlight exhibit especi interact product bioactiv product
bioengin skin skin substitut topic abil meaning penetr market like
predic post-approv studi demonstr efficaci specif wound heal well
posit potenti commerci partner
bioengin skin skin
page
topic project revenu chronic wound grow
million believ major chronic wound treat diabet ulcer also
expect pressur ulcer venou stasi ulcer burn treat topic due
fragment wound care market lack clinic data topic treat chronic wound
project peak market share approach believ project could prove
conserv obtain meaning clinic data secur strong commerci partner
exhibit topic revenu project chronic wound burn care
page
europ project topic revenu chronic wound grow million
million believ major chronic wound treat diabet ulcer also
expect pressur ulcer venou stasi ulcer burn treat topic europ
reduc peak market share expect anticip price similar
 believ project could prove conserv obtain meaning clinic data
secur strong commerci partner
exhibit topic revenu project european chronic wound burn care
expect seek commerci partnership sell topic surgic territori
believ could attain partner topic earli compani receiv clearanc
topic estim current assum royalti rate topic revenu
royalti rate surgic revenu up-front mileston payment certainli possibl
remain upsid current model estim target total revenu
grow million
page
total royalti arth
reason invest arth bad break dealt fda could present buy opportun
believ market overreact agenc concern sensit
last year therapeut verg receiv first regulatori decis fda
file topic extern use submit juli time arth
trade around market cap million decemb final day
fda review period agenc relay late-g question abil sensit immun
system human caus allerg reaction despit anim data demonstr non-
sensit posit result cumul irrit studi human one patient obtain
rash clinic safeti efficaci studi compani felt best cours action
voluntarili withdraw submiss engag agenc better understand concern
meanwhil investor fled sidelin stock price fell consider million market
arch present annual roth confer march investor unawar
detail lead mani believ manufactur issu someth els march
compani reveal sensit issu hand submit propos
agenc conduct addit two-month clinic studi test sensit human skin unlik
cumul irrit studi propos studi subject would receiv topic two separ
occas separ sever week sensit skin ige antibodi would develop
treatment would trigger allerg respons follow subsequ exposur provid
propos accept compani plan begin studi may resubmit file data
along addit evid scientif literatur expert testimoni end
target approv year-end expect quick turnaround time agenc
understand market reaction initi news decemb believ investor
fail appreci chang risk/reward balanc follow arch march updat overal
updat increas outlook likelihood approv compar withdraw
evid point sensit believ would highli unlik
propos studi demonstr sensit theoriz order penetr
skin interact immun system chemic compound would need dalton size
dermatol sinc averag amino acid dalton glycin smallest amino
acid dalton larg believ singl peptid unit made amino
acid deem highli unlik test demonstr sensit skin addit
believ unlik agenc bring new concern would
expect happen decemb howev scenario still possibl well refus accept
arch propos believ scenario unlik therefor thing consid equal
confid march updat likelihood approv
page
appreci fact news like delay commerci timelin topic six
month surgic upward one year compani potenti need pursu
addit dilut financ prior receiv regulatori approv howev believ market
current valuat valu arth share prior withdraw demonstr
underappreci risk/reward profil shift sinc march updat
reason invest arth valuat appear attract
resum coverag buy rate price target arriv
price target sum-of-the-part analysi topic valu
surgic valu rest arch pipelin remain upsid current
project util royalti multipl valuat approach topic surgic
topic assign royalti multipl project royalti million risk-adjust
estim probabl approv discount eight year equat
valuat topic assum million common share surgic assign
royalti multipl project royalti million risk-adjust estim probabl
approv discount eight year equat valuat surgic
assum million common share support valuat multipl
ep project discount back six year work
impedi share reach price target includ limit regulatori risk financi risk
partnership risk competit risk
probabl approv
probabl approv
page
catalyst valuat adjust
addit quarterli financi result catalyst could revalu compani share higher lower
come month list
page
resum coverag buy rate price target arriv
price target sum-of-the-part analysi topic valu
surgic valu rest arch earlier-stag pipelin remain upsid
current project util royalti multipl valuat approach topic surgic
topic assign royalti multipl project royalti million risk-adjust
estim probabl approv discount eight year equat valuat
topic assum million common share surgic assign royalti
multipl project royalti million risk-adjust estim probabl approv
discount eight year equat valuat surgic assum million
common share support valuat multipl ep project
share discount back six year work
impedi share reach price target includ limit regulatori risk financi risk
partnership risk intellectu properti risk competit risk
addit risk inher develop manufactur sell medic devic key invest
risk includ
regulatori risk arth plan seek fda european regulatori approv topic
surgic failur correspond occur within rang expect could materi
advers impact compani share
partnership risk arth plan seek commerci partnership asset territori
manufactur market distribut failur acquir partner partner reach reason
term potenti partner could materi advers impact compani share
financi risk arth like need addit financi resourc complet busi model failur
compani attain resourc reason term could materi advers impact
intellectu properti risk arth sap technolog back ip portfolio includ patent
own exclus licens arth failur arth maintain updat intellectu properti
portfolio could materi impact arth share
competit risk arth develop product highli competit market inabl penetr
market result unfavor financi result could materi advers impact compani share
inc development-stag compani compani oper biotechnolog
compani compani focus develop product stop bleed hemostasi control leak
sealant surgeri trauma care compani technolog base self-assembl peptid
creat physic mechan barrier could appli seal organ wound leak
blood fluid compani primari product candid collect known devic
design achiev hemostasi surgic procedur compani product candid reli
self-assembl peptid technolog design achiev hemostasi skin wound minim
invas open surgic procedur compani focus develop product candid base
technolog platform use rang indic decemb compani
gener revenu
page
revenu earn model
valu
good sold revenu
gener administr expens
research develop expens
total incom expens
net incom tax
provis incom tax
ep basic dilut
weight common share basic dilut
arth sec file roth capit partner forecast
page
valu
equival
properti equip net
accru expens current liab
accru interest relat parti
total liabil stockhold equiti
page
statement flow
valu
non-cash interest expens note payabl
issuanc restrict stock servic
exercis warrant convers debt
loss warrant deriv modif net induc
decreas increas fair valu deriv
fair valu deriv liabilit excess proce
issuanc common stock servic
chang oper
prepaid expens current asset
accru expens liabil
purchas properti equip
proce issuanc common stock warrant net
proce exercis warrant
proce exercis stock option
proce issuanc convert note
proce issuanc note payabl
payment note payabl
chang cash
begin period
end period
page
pma ce mark file
pma ce mark clearanc
page
